Do you want to read an article? Please log in or register.
Durvalumab consolidation therapy in a patient with stage IIIB unresectable NSCLC harboring a MET exon 14 splice site alteration
Lung Cancer
Related content
RECOMMENDED
Lung Cancer
Real-world insights into patients with advanced NSCLC and MET alterations
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Bittoni M, Yang JC, Shih JY, Peled N, Smit EF, Camidge DR, Arasada RR, Oksen D, Boutmy E, Stroh C, Johne A, Carbone DP, Paik PK
doi: 10.1016/j.lungcan.2021.06.015
RECOMMENDED
Lung Cancer
MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Lung Cancer
Wong SK, Alex D, Bosdet I, Hughesman C, Karsan A, Yip S, Ho C
doi: 10.1016/j.lungcan.2021.02.030
RECOMMENDED
Lung Cancer
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study
★ 1
Recommended by
Prof. Dr Stephan Bodis, Faculty Member
★ 2
Recommended by
Alexander Meisel, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Oncol.
Hui R, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Gray JE, Rydén A, Viviers L, Poole L, Zhang Y, Dennis PA, Antonia SJ
doi: 10.1016/S1470-2045(19)30519-4.
RECOMMENDED
Lung Cancer
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
★ 2
Recommended by
Dr Martin Frey, Faculty Member
N Engl J Med.
Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X
doi: 10.1056/NEJMoa2004407.
RECOMMENDED
Lung Cancer
Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Lung Cancer
Joshi K, Muhith A, Obeid M, Milner-Watts C, Yousaf N, Popat S, Davidson M, Bhosle J, O'Brien M, Minchom A
doi: 10.1016/j.lungcan.2021.04.021
RECOMMENDED
Lung Cancer
Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP)
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer.
Faehling M, Schumann C, Christopoulos P, Hoffknecht P, Alt J, Horn M, Eisenmann S, Schlenska-Lange A, Schütt P, Steger F, Brückl WM, Christoph DC
doi: 10.1016/j.lungcan.2020.10.006.Visit the original publication at ncbi.nlm.nih.gov
RECOMMENDED
Lung Cancer
Identifying advanced stage NSCLC patients who benefit from afatinib therapy using 18F-afatinib PET/CT imaging
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
van de Stadt EA, Yaqub M, Lammertsma AA, Poot AJ, Schuit RC, Remmelzwaal S, Schwarte LA, Smit EF, Hendrikse H, Bahce I
doi: 10.1016/j.lungcan.2021.03.016
RECOMMENDED
Lung Cancer
Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Passiglia F, Leone G, Olmetto E, Delcuratolo MD, Tabbò F, Reale ML, Bertaglia V, Consito L, Bironzo P, Capelletto E, Novello S
doi: 10.1016/j.lungcan.2021.05.009
RECOMMENDED
Lung Cancer
Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Ther Adv Respir Dis.
Botticella A, Mezquita L, Le Pechoux C, Planchard D
doi: 10.1177/1753466619885530.